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The dynamic process oflysineacetylationanddeacetylationis
fundamental to chromatin remodelling and the regulation of
gene-speciﬁc transcription.
1,2 Histone acetyl transferases pro-
mote N-acetylation of ε-lysine tails on histone proteins, whereas
histone deacetylases (HDACs) catalyze the remove of acetyl
groups, leading to transcriptional repression via a condensed
chromatin where DNA is wrapped tightly around the positively
charged histone core. The consequence of the latter is transcrip-
tional silencing, which, in cancer, contributes to evasion of
apoptosis and cancer progression. HDACis (HDAC inhibitors)
are attractive anticancer agents since restoring a relaxed, hyper-
acetylated, chromatin structure leads to gene transcription and
the upregulation of a number of proapoptotic and growth arrest
proteins (e.g., p21/cip1). Modulation of acetylation of nonhis-
tone proteins may also contribute to anticancer eﬀects (e.g., p53,
hsp90). Vorinostat 1 (SAHA, suberoylanilide hydroxamic acid)
isthearchetypalHDACi.
37Ithasbeenapprovedforclinicaluse
against cutaneous T-cell lymphoma (CTCL) and shown to
synergize with many anticancer agents including kinase
inhibitors and proteasome inhi b i t o r sa sw e l la sr a d i a t i o n
therapy.
810
A number of recent publications have explored subtle manip-
ulations of the so-called “cap-tail-linker” pharmacophore of
SAHA to probe structureactivity relationships (SARs) and
bindingmodes(Figure1).HDACinhibitoryactivityisimproved
bythepresenceofelectron-donatinggroupsonthearylcap,asin
the dimethyl analogue 2, with the exception of ortho substitu-
ents, which lead to decreased activity due to steric clashes upon
enzymebinding.
11Otherresearchgroupshaveprobedtheeﬀects
ofsubstituentsonthephysiochemicalproperties andselectivities
of HDACis as in the branched analogues 3a and 3b.
12,13 Alkyl
substitutents adjacent to the hydroxamic acid lead to a loss of
HDAC inhibitory action as in 3c, attributed to conformational
disruption of binding of the hydroxamic acid to zinc in the active
site of the enzyme.
14,15
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ABSTRACT: N
1-Hydroxy-N
8-ferrocenyloctanediamide, JAHA
(7),anorganometallicanalogueofSAHAcontainingaferrocenyl
group as a phenyl bioisostere, displays nanomolar inhibition of
class I HDACs, excellent selectivity over class IIa HDACs, and
anticancer action in intactcells (IC50=2 . 4μM, MCF7cellline).
Molecular docking studies of 7 in HDAC8 (a,b) suggested that
the ferrocenyl moietyin7canoverlapwiththearylcapofSAHA
and should display similar HDAC inhibition, which was borne
out in an in vitro assay (IC50 values against HDAC8 (μM, SD in
parentheses): SAHA, 1.41 (0.15); 7, 1.36 (0.16). Thereafter, a
smalllibraryofrelatedJAHAanalogueshasbeensynthesized,and
preliminary SAR studies are presented. IC50 values as low as 90
pM toward HDAC6 (class IIb) have been determined, highlighting the excellent potential of JAHAs as bioinorganic probes.
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We describe herein our preliminary ﬁndings on designing a
metal-based SAHA analogue to probe the eﬀect of a nonplanar
phenyl bioisostere, namely, a ferrocene unit, on HDAC inhibi-
tory action. A recent study showed SAHA-cis-platin hybrids to
have low micromolar activity against HDACs and cancer cell
lines,
16 and previous studies from ours and other groups have
shown that ferrocene analogues can display impressive antic-
ancer activity and act as eﬀective metallodrugs and bioinorganic
probes.
1719
The microwave-mediated reaction of ferrocenylamine 4 with
methyl-8-chloro-8-oxooctanoate 5 aﬀorded the methyl ester 6
(Scheme1). High yields were observed whenemploying triethy-
lamine as a base as opposed to a polystyrene-supported base.
Moreover, the former procedure obviated the need for a chro-
matographic puriﬁcation step. Next, reaction of 6 with hydro-
xylamine,generatedinsitufromitsHClsalt,aﬀordedthedesired
compoundJayAminhydroxamicacid(JAHA)7,inanoverall ca.
50% yield. Using related synthetic procedures, a small library of
JAHA analogues was synthesized for SAR investigation. Hence,
the homologated ferrocene 8 (homo-JAHA) was made to probe
the eﬀect of introducing a methylene spacer in 7. A number of
aryl-linker JAHA analogues were next synthesized viz. the ortho-
and para-ferrocenyl-substituted 911, respectively, to evaluate
the eﬀect of the organometallic group linked to a parent SAHA
molecule.
Thestructuresofthemethylesterintermediatesto7,8,and9,
namely,6,12,and13wereinvestigatedinthesolidstatebyX-ray
crystallography to ascertain the presence of the ferrocene group
and to assist our modeling studies on 7 (Figure S2 and Table S1
in the Supporting Information).
The incorporation of organometallic moieties into protein
ligandsbringsthepotentialbeneﬁtofﬁllingspaceinawaythat
is not possible with simple planar aromatic groups or alicyclic
ring systems, which can enhance aﬃnity.
20,21 In addition,
ligands that contain organometallic groups can enable X-ray
structure determination of proteinligand complexes by
facilitating phasing. To explore the binding mode of 7 in
deacetylases, we performed docking studies, using the struc-
ture of an HDAC8-SAHA complex as a starting point.
22 We
found that 7 is able to bind in a similar mode to SAHA,
exploiting archetypal interactions between the hydroxamate
andthecatalyticzinc,togetherwithahydrogenbondbetween
Figure 1. SAHA and analogues.
Scheme 1
a
aReagents: (a) Base = PS-NMM, and yield = 23%. (b) Base = NEt3, and yield = 74%; THF, 20 min, μW, 150  C, 150 W. (c) KOH, NH2OH3HCl,
MeOH, 70%.
Figure 2. Docked 7, 9 andcomparison to SAHA.(a)Docked7 inthe
active site of HDAC8. (b) Comparison of 7 to cocrystallized SAHA
(PDB code: 1t69). (c and d) Docked 9 in HDAC8 (superimposed
over SAHA in panel c). The zinc ion is depicted in cyan. The residues
in the binding pocket and ligands are shown in ball and stick
representation. Color coding: nitrogen, blue; oxygen, red; carbon,
gray in protein, light green for 7, and orange for SAHA; and yellow
for 9.360 dx.doi.org/10.1021/ml100295v |ACS Med. Chem. Lett. 2011, 2, 358–362
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the amide moiety of the ligand and Asp101. The ferrocenyl
group of 7 is comfortably accommodated in the shallow
pocket formed by Tyr100, Phe152, and Tyr306; this region
of the enzyme is reported to be malleable and able to adapt to
structures of diﬀerent ligands. This binding mode suggested
that 7 and SAHA should display similar potencies as HDACis
(Figure 2).
Compound 9, with the ferrocene group substituted at the
ortho-position onthephenylgroup ofSAHA,isdockedsimilarly
(Figure 2c). The phenyl ring is twisted when compared with
cocrystallized SAHA. With the insertion of the phenyl group,
when compared to compound 7, the ferrocene group of com-
pound 9is pushedfurther down tothe subpocket of the enzyme,
leading to a better ﬁt in the hydrophobic groove formed by Phe
152 and Tyr306 as well as Lys33 and Met274 (Figure 2d). The
close van der Waals interactions between the ferrocene group
and the residues in the subpocket could potentially increase the
aﬃnity of compound 9.
Compound7wastestedforinhibitoryactionagainstclassI,
IIa, and IIb HDACs (19) and compared with the related
SAHA 1. Both have similar broad HDAC inhibitory proﬁles,
exhibiting similar IC50 values, including for HDAC8, which
gratifyingly consolidates our modeling studies (Table 1).
Compound 8 has a similar proﬁle to that of 7 for HDACs
13,althoughitisca.10-foldlesspotenttowardHDAC6and
four times more potent toward HDAC8. Compound 10
considerably outperforms the other ferrocenes as well as
SAHA toward HDACs 1, 2, and notably, against the class
IIb,HDAC6(IC50=90pm) ,whereas9 showsthelowestIC50
value toward HDAC8 with a IC50 = 2 nM. Compound 11,a
shorter length analogue of 10, displayed poor HDAC inhibi-
tion, underpinning the importance of chain length on HDAC
inhibition. None of the compounds 711 showed any sig-
niﬁcant inhibition of class IIa HDACs (4, 5, 7,a n d9),
23 and
data are not shown.
Critical to the development of chemical probes targeting
HDACs is the demonstration of activity in a cellular environ-
ment. The compounds were tested for cytotoxicity against a
breast cancer cell line, and the results are given in Table 2.
24
SAHA 1 is the most cytotoxic of the series with all of the
ferrocenes displaying single digit micromolar activities. Ana-
logues 9 and 10 are less cytotoxic than 1,w h i c hm a yr e ﬂect
reduced cellular penetration due to the presence of the
ferrocene group.
Additionally, propidium iodide-staining experiments de-
monstrated that 7 and 10 also induced cell cycle arrest and
cell death in MCF7 cells (Figure S1 in the Supporting
Information). Consistent with eﬀects of other HDACis,
the compounds decreased the proportion of cells in the G1
and S phases of the cell cycle, associated with an accumula-
tion of cells in G2M.
25 The compounds also increased the
proportion of cells with sub-G1 DNA content, a marker of
cell death.
Toassesstheactivityofleadcompoundsemergingfromthis
research, we cultured K562 erythroleukemia cells with com-
pounds 9 and 10 and performed ﬂow cytometry to quantify
changes in bulk chromatin acetylation (the endogenous sub-
strate of class I deacetylases) and acetylation of R-tubulin
(a substrate of HDAC6). As shown in Figure 3, cells treated
with 9 and 10 (10 μM) produced comparable histone
and tubulin acetylation as the FDA-approved HDACi 1
(Figure 3).
JAHA analogues have been synthesized in good yields
using a crucial expedited microwave-mediated amide cou-
pling reaction prior to the attachment of the hydroxamic acid
zinc binding moiety. Many, apart from 11, display excellent
broad class I HDAC inhibition although, for HDAC8, IC50
valuesaremainlyinthemicromolarrange,withtheexception
of9(IC50=2nM).Nanomolarorsubnanomolarinhibitionof
the class IIb HDAC6 was also observed. These results
establish that the three-dimensional manipulation of the aryl
“cap” of SAHA 1 is a viable strategy for the synthesis of
HDACis. Because HDAC inhibition is often improved, these
resultssuggestthattheuseofnonplanarcapgroupsmayhave
broader potential in HDACi design. Current studies are
aiming to synthesize JAHA analogues by changing the cap
(metal/coligands),linker,andbindinggroupsforSARstudies
and employing these analogues as structural probes. Further
studies have conﬁrmed the cell permeability of compounds 9
and10andidentifyattractivepotencyagainstclassIandclass
II HDACs in a cellular context.
25 Compounds 9 and 10 hold
promise as bioinorganic probes for HDACs, and we are
currently actively investigating their potential for obtaining
cocrystal structures in HDACs as well as studies in vivo
including Xenopus.
26,27
Table 1. IC50 Values for HDACis versus SAHA (1)
a
analogue HDAC1 HDAC2 HDAC3 HDAC6 HDAC8
1 0.001 (0.0002) 0.002(0.0007) 0.003(0.0004) 0.00049(0.00010) 1.41(0.15)
7 0.011(0.002) 0.011 (0.003) 0.018(0.004) 0.0008(0.0001) 1.36(0.16)
8 0.033(0.005) 0.039(0.0086) 0.072 (0.011) 0.0067(0.0009) 0.29(0.02)
9 0.0107(0.002) 0.010(0.0026) 0.008(0.001) 0.0003 (0.00006) 0.002(0.0002)
10 0.0005(0.0004) 0.0006(0,0001) 0.009(0.0018) 0.00009(0.00005) 0.54(0.07)
11 2.56(0.34) 3.04(0.16) 3.17(0.22) 1.40(0.13) 6.07(1.18)
aIC50 values for compounds (μM) with SD in parentheses. Assays were performed in duplicate.
Table 2. Cytotoxicity of JAHAs and SAHA in MCF7 Breast
Cancer Cell Lines
analogue IC50 (μM) with SD
a
1 0.73(0.38
7 2.44(0.54
8 3.60(0.48
9 1.90(0
10 3.13(1.08
11 5.08(0.55
aMCF7 cell line. Mean value of a minimum of two assays.361 dx.doi.org/10.1021/ml100295v |ACS Med. Chem. Lett. 2011, 2, 358–362
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